Abstract CT250: Trofuse-023: A phase 3, randomized, open-label study of pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT) as first-line treatment for metastatic squamous non-small-cell lung cancer (NSCLC) | Publicación